TerminatedPhase 1
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
Key facts
- Who runs it
- CRISPR Therapeutics AG
- Where
- Canada2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 5 people enrolled
- Started
- 20 Jan 2023
- Ended
- 8 Aug 2025
- Type of study
- Interventional
- Treatments tested
- VCTX211
- Record updated
- 7 May 2026
- Why it stopped
- Patients to be followed up in the VCTX-201 study
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Diagnosis of T1D for a minimum of 5 years
- Stable diabetes regimen for at least 3 months prior to enrollment
Who cannot take part
- Occurrence of 2 or more severe, unexplained hypoglycemic events within 6 months prior to enrollment
- Immunosuppressant therapy in the previous 30 days and/or requirements for chronic immunosuppressive therapy during the study
- Prior treatment with gene therapy or edited product
- Medical history of islet cell, kidney, and/or pancreas transplant
- Known causes of diabetes other than T1D
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label, multicenter, Phase 1 study evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects with T1D
The group in the trial
- VCTX211 unitTreatment being tested
Treatment: VCTX211
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
- Publications
- Gene Therapy and Gene Editing in Type 1 Diabetes: CRISPR-Based β-Cell Replacement and Treg Immune Modulation Approaches.Diabetes, obesity & metabolism, 2026
- Record updated
- 7 May 2026